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White blood cellsRecent research suggests that epigenetic alterations involving DNA methylation can be causative for
neurodevelopmental, growth and metabolic disorders. Although lymphoblastoid cell lines have been an
invaluable resource for the study of both genetic and epigenetic disorders, the impact of EBV transformation,
cell culturing and freezing on epigenetic patterns is unknown. We compared genome-wide DNA methylation
patterns of four white blood cell samples, four low-passage lymphoblastoid cell lines pre and post freezing
and four high-passage lymphobastoid cell lines, using two microarray platforms: Illumina HumanMethyla-
tion27 platform containing 27,578 CpG sites and Agilent Human CpG island Array containing 27,800 CpG
islands. Comparison of genome-wide methylation proﬁles between white blood cells and lymphoblastoid
cell lines demonstrated methylation alterations in lymphoblastoid cell lines occurring at random genomic
locations. These changes were more profound in high-passage cells. Freezing at low-passages did not have a
signiﬁcant effect on DNA methylation. Methylation changes were observed in several imprinted differentially
methylated regions, including DIRAS3, NNAT, H19, MEG3, NDN and MKRN3, but not in known imprinting
centers. Our results suggest that lymphoblastoid cell lines should be used with caution for the identiﬁcation
of disease-associated DNA methylation changes or for discovery of new imprinted genes, as the methylation
patterns seen in these cell lines may not always be representative of DNA methylation present in the original
B-lymphocytes of the patient.
© 2009 Elsevier Inc. All rights reserved.Introduction
Immortalized lymphoblastoid cell lines (LCLs) are of great
practical value for human genetics, because they provide a virtually
unlimited source of DNA. Many publicly available research reposito-
ries store LCLs derived from both healthy individuals and individuals
with various disorders. These cell lines have been particularly useful
for genetic studies despite rare cases of genomic instability [1].They
have also been successfully used for gene expression analyses in
neuropsychiatric disorders [2,3]. Given the attention focused now on
discovery of epigenetic determinants in human disorders, we studied
the stability of epigenetic marks in LCLs, easily accessible cell lines for
such research.
DNA methylation is an important epigenetic mechanism regulat-
ing gene expression. It occurs predominantly at cytosines of CpG
dinucleotides. CpGs are distributed non-randomly in the genome. For
98% of the genome, CpG sites occur at low frequency once per 80
dinucleotides. CpG islands range in size from 200 bp to several kb,olic Genetics, Hospital for Sick
Canada M5G 2L3. Fax: +1
eksberg).
ll rights reserved.comprise 1–2% of the genome, and have a ﬁve-fold higher concen-
tration of CpGs than the rest of the genome [4]. The CpG islands
commonly associated with gene promoters are usually not methyl-
ated. Important exceptions are the imprinted genes and genes on the
inactive X chromosome [4]. Normally methylation of promoters
containing CpG islands causes gene silencing. However, for CpG poor
promoters there are conﬂicting reports about the effect of methyla-
tion on gene expression [5,6].
Aberrant DNA methylation can result in various disorders
including cancer [7] and imprinting disorders [8,9]. Whole genome
based approaches such as microarrays and deep genome sequencing
have presented new opportunities to identify epigenetic defects
associated with human diseases. In many cases, DNA from LCLs might
be considered the best available material for such experiments.
However, the essential question is: normal methylation marks
retained in LCLs? There are several factors that could potentially
change methylation patterns in LCLs as compared to B-lymphocytes,
from which they originate. These include Epstein Barr virus infection
and subsequent immortalization, cell culture conditions and freezing
cycles. Two types of altered methylation patterns could theoretically
occur. De novo methylation of normally unmethylated sequences
could occur via DNA methyltransferase activity. Alternatively, loss of
methylation could occur either passively through failure of DNA
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by demethylating activity; however no enzyme with such activity has
been identiﬁed to date. If DNA methylation changes were to occur in
LCLs at speciﬁc genomic locations, this would not be a problem for
epigenetic research, as the probes for these genomic regions could be
excluded from the analysis. However, if methylation changes occur at
random genomic locations in LCLs, this could invalidate experiments
targeting the identiﬁcation of candidate DNA methylation changes
associated with a speciﬁc disease. This is because it would not be clear
whether the altered DNA methylation pattern represents the original
patient's DNA proﬁle or whether it reﬂects in vitro changes that occur
during cell line establishment and maintenance.
Our experiments were designed to explore the scope of epigenetic
alterations occurring in LCLs and how that might impact the use of
these lines for epigenetic discoveries. We compared genome-wide
DNA methylation proﬁles from LCLs and white blood cells (WBCs)
using two technologies: methylated DNA immunoprecipitation
followed by Agilent CpG island array (27,800 CpG islands) and
Illumina's Inﬁnium HumanMethylation27 BeadChip (27,578 individ-
ual CpG dinucleotides spanning 14,495 genes). Our goal was to
determine the utility of these two platforms to identify methylation
changes in comparisons of methylation proﬁles of WBCs and LCLs. We
compared four WBC samples, four low passage LCLs (LP_LCLs) and
four low passage LCLs after freezing (FR_LCLs) from the same
individuals and four unrelated high passage previously frozen LCLs
(HP_LCLs). We used both Illumina and Agilent platforms for genome-
wide correlation analysis and analysis of DNA methylation changes in
imprinted genes. The Agilent platform was used for differential
methylation analysis of one WBC and LP_LCL pair in order to select
regions of several hundred bps with methylation changes, as except
for imprinted genes Illumina coverage was limited to two CpG sites
for most genes. The Illumina array and pyrosequencing were used to
validate differences detected by Agilent in a larger number of LP_LCL
pairs.
Our results show that the various technologies we used validate
each other in identifying DNA methylation changes. We found
random methylation changes in LP_LCLs, FR_LCLs and HP_LCL; the
largest frequency was in HP_LCLs. The methylation proﬁles in FR_LCLs
were similar to LP_LCLs, indicating that one cycle of freezing does not
induce signiﬁcant methylation changes.
We also checked DNA methylation patterns at differentially
methylated regions of imprinted genes. Imprinted genes are
expressed from only one of the parental alleles. There are approxi-
mately 60 imprinted genes found in the human genome (http://
www.geneimprint.com). There are a number of single imprinted
genes (e.g. DIRAS3, NAP1L5, NNAT) but the majority identiﬁed to date
are clustered in the genome [10]. The parent-of-origin speciﬁc
expression of imprinted genes within the cluster is usually regulated
by allelic methylation at a single imprinting centre (IC), and often
additional differentially methylated regions (DMRs) are present
within the cluster, usually within the promoters of the imprinted
genes. These parent of origin speciﬁc allelic methylation patterns are
maintained in somatic cell lineages, with few exceptions [8].
However, it is not known whether this differential allelic methylation
is consistently maintained in immortalized LCLs. Our results showed
that several imprinted DMRs, but none of the known ICs, have
methylation changes. These occur in all type of LCLs, with more
changes occurring in HP_LCLs.Results
We compared DNA methylation between WBCs and LCLs at two
levels of resolution: CpG islands and single CpG sites, using two
microarray platforms, the Illumina HumanMethylation27 BeadChip
and the Agilent CpG island array. For the Agilent array, themethylatedDNA immunoprecipitation (MeDIP) was carried out prior to
hybridization.
MeDIP is a recently developed technique [11] used to capture
methylated DNA sequences.We labeled the immunoprecipitated DNA
and input DNA with two different ﬂuorescent dyes and co-hybridized
to the Agilent microarrays. Log2 ratios of immunoprecipitated DNA
versus input (MeDIP/Input) were used to assess the levels of
methylation with higher log2 ratios representing higher levels of
methylation. The log2 (MeDIP/Input) is not an absolute methylation
value, but can be used to compare methylation levels between
samples at the same genomic locations (i.e. microarray probes), but
not to comparemethylation levels among different genomic locations,
as MeDIP enrichment depends on the density of the methylated CpG
sites [11,12]. The Illumina platform utilizes bisulphite converted DNA
and thus measures absolute methylation levels at speciﬁc CpG sites.
The methylation level of each site is measured as C/(C+T) and is
represented as a β value ranging continuously from 0 (0%methylated)
to 1 (100% methylated).This method provides more accurate
methylation level measurements than MeDIP, but less genomic
coverage as only one CpG site is measured by each array probe.
We implemented both of the above described techniques in order
to study DNA methylation stability in LCLs. We assessed changes in
DNAmethylation for DNA fragments 500 bp and longer by MeDIP and
Agilent CpG island microarray and the DNA methylation changes
occurring at speciﬁc CpG sites by Illumina methylation platform.
To assess the methylation differences between DNA from WBCs
and LCLs, we analyzed methylation proﬁles for four sets of WBCs, low
passage LCLs, and frozen LCLs from two males and two females
(WM1/LM1_LP/LM1_FR, WM2/LM2_LP/LM2_FR, WF1/LF1_LP/
LF1_FR, WF2/LF2_LP/LF2_FR) using the Illumina platform, and one
pair of WBC and low passage LCL (WM1/LM1_LP) using MeDIP and
the Agilent platform (Table 1). DNA was extracted from the low
passage LCLs directly after EBV transformation prior to freezing the
cells, and then DNA was extracted a second time after one cycle of
freezing (frozen LCLs). Four high passage LCLs (LM3_HP, LF3_HP,
LM4_HP, LPID11_HP) had undergone an unknown number of freezing
cycles and cell divisions, and were studied using the Illumina array;
and two of them (LF3_HP and LPID11_HP) using the Agilent array. As
well, one un-paired WBC sample (WF4) was studied with the Agilent
array (Table 1).
Comparison of genome-wide DNA methylation levels between LCLs
and WBCs
DNA methylation across the genome was assessed to determine
consistency among WBCs versus LCLs. We ﬁrst assessed cell type
speciﬁc differences between WBC and three types of LCLs by
performing Manhattan hierarchical clustering analyses of Illumina
methylation data. Clustering showed that WBC samples and LCLs
cluster in separate groups, whereas there was no clustering of LCLs
according to the type (low passage, frozen, high passage) (Fig. 1). This
suggests that DNA methylation changes in each group could be
either speciﬁc for the group or random.
To further assess cell type speciﬁc differences, we compared
genome-wide DNA methylation proﬁles between individual samples
by calculating correlation coefﬁcients (R) for linear regressions of
pair-wise sample comparisons. Sex chromosomes (X and Y) were
excluded from these analyses, in order to pick up only cell type
speciﬁc differences, but not sex speciﬁc differences.
Illumina methylation correlations
Correlation coefﬁcients (R) for Illumina methylation are shown in
Table 1A. R values among WBC samples ranged from 0.985 to 0.99
(Table 2A), showing very small inter-individual variation in the DNA
methylation of WBCs. However, for pairs of WBCs and LCLs from the
same individuals, R values were in range of 0.933–0.947 for WBC/
Table 1
Samples used in the study.
Samples Cell type Sex Age, years Source Disease Coriell ID Platform used Frozen before DNA extraction
WM1 WBC M 26 HSCa Healthy N/a Agilent, Illumina N/A
LM1_LP LP_LCL M 26 HSC Healthy N/a Agilent, Illumina No
LM1_FR LP_LCL M 26 HSC Healthy N/a Illumina Yes
WM2 WBC M 35 HSC Healthy N/a Illumina N/A
LM2_LP LP_LCL M 35 HSC Healthy N/a Illumina No
LM2_FR LP_LCL M 35 HSC Healthy N/a Illumina Yes
WF1 WBC F 33 HSC Healthy N/a Illumina N/A
LF1_LP LP_LCL F 33 HSC Healthy N/a Illumina No
LF1_FR LP_CLC F 33 HSC Healthy N/a Illumina Yes
WF2 WBC F 28 HSC Healthy N/a Illumina N/A
LF2_LP LP_LCL F 28 HSC Healthy N/a Illumina No
LF2_FR LP_LCL F 28 HSC Healthy N/a Illumina Yes
LM3_HP HP_LCL M 13 Coriellb Healthy GM06998 Illumina Yes
LF3_HP HP_LCL F 12 Coriell Healthy GM12244 Agilent, Illumina Yes
LM4_HP HP_LCL M 10 Coriell Healthy GM03798A Illumina Yes
WF4 WBC F 0 HSC Healthy N/a Agilent N/A
LPID11_HP HP_LCL F 1 HSC UPD11. BWS N/a Agilent, Illumina Yes
LF5_LP LP_LCL F 7 HSC Healthy N/a Pyro No
WF5 WBC F 7 HSC Healthy N/a Pyro N/A
For sample names the 1st letter indicates cell type (L for lymphoblastoid cell line, W for white blood cells), the 2nd letter indicates sex (M for male, F for female), and the third digit is
individual number. If the number is the same, it means the sample originated from the same individual. The exception is LPID11 sample, which is a lymphoblastoid cell line having
paternal isodisomy for chromosome 11. LP means low passage, HP means high passage, FR means the cell line was frozen before DNA extraction. N/A means not available.
a Hospital for Sick Children, TCAG, Biobanking facility (Toronto).
b NGIMS Human Genetics Cell Repository, Coriell Institute of Medical Research (Camden, NJ).
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methylation proﬁles in LCLs are not identical to the original WBC
samples, either due to the EBV transformation or to the different cell
composition, as only B lymphocytes are transformed into LCLs. The
correlation is very similar forWBCs/LP_LCLs andWBCs/FR_LCLs pairs,
suggesting that one cycle of freezing does not affect genome-wide
DNA methylation any more than short term culturing.Fig. 1. Manhattan hierarchical clustering of Illumina methylation data from WBCs and
LCLs. Dendogram shows the 2 main branches, WBCs and LCLs.We hypothesized that if DNA methylation patterns changed at the
same genomic locations in all LCLs, the correlation between LCLs
would be very similar to the correlation among WBCs. However, we
observed small but signiﬁcant decreases of correlation coefﬁcients
between LP_LCL samples (R=0.960–0.982, p-value 0.002, paired t-
test) and FR_LCL (R=0.976–0.984, p-value 0.013) compared to WBC
samples (R=0.985–099). Thus, these data indicate that EBV transfor-
mation and short-term culture can induce random DNA methylation
changes. However one cycle of freezing does not induce increased
methylation differences compared to short term culture only.
We further tested DNA methylation in the 4 HP_LCLs that were
cultured for a higher number of cell divisions than low passage/frozen
cell lines. We did not have matching DNA samples fromWBCs for the
HP_LCLs and were not able to track howmany cell divisions these cell
lines had undergone or how many times they were frozen prior to
DNA extraction. Correlation coefﬁcients for the pair-wise comparisons
of DNA samples from HP_LCLs were in range of 0.905–0.955
(Table 2A). This is signiﬁcantly lower than the correlations for WBCs
(p-value=0.0008) and LP_LCLs (p-value=0.004, un-paired t-test).
This reduction in correlation indicates that prolonged cell culturing
and repeated freeze–thaw cycles induce progressive random changes
in DNA methylation.
Agilent/MeDIP methylation correlations
MeDIP and Agilent CpG island microarray was performed on 5
samplesWM1 and LM1_LP, WF4 (WBC DNA from a new-born female)
and LF3_HP and LPID11_HP (Table 1). We performed pair-wise
comparisons of all microarray data points in quantile normalized log2
ratios of MeDIP/input. Linear-regression correlation coefﬁcients (R)
are shown in Table 2B.
We observed the same trend in this experiment as for the Illumina
interrogation. The methylation correlation among two WBC samples
run on the Agilent microarray was higher or equal but not lower than
correlations between LCL samples. The inter-individual correlation for
the WM1_WF4 sample pair run on Agilent was slightly lower (0.972)
than for WBC samples (WM1, WM2, WF1, WF2) run on the Illumina
microarray (0.985–0.990). This could reﬂect speciﬁc methylation
differences of one particular sampleWF4, as this sample was collected
from a newborn cord blood, whereas the other WBC samples were
from adults.
Table 2
Correlation coefﬁcients (R) of pair-wise comparisons of all data points (excluding sex chromosomes) between samples run on the Illumina array (A) and Agilent array (B).
WBC samples are highlighted in black, LP_ LCLs are highlighted in white, FR_LCLs are highlighted in light grey, and HP_ LCLs are highlighted in dark grey.
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Known DNA methylation abnormalities in two imprinting centers
were used to verify the capability of the Illumina and Agilent
platforms to detect methylation changes. We used a DNA sample
from a LCL with paternal isodisomy of chromosome 11 in 85–90% of
the cells (LPID11_HP). This cell line from a patient with Beckwith–
Wiedemann syndrome was known to carry methylation abnormali-
ties at two imprinting centers on chromosome 11p15.5, gain of
methylation at the paternal H19 DMR and loss of methylation at the
maternal KvDMR [10]. We observed the expected loss of methylation
at KvDMR on both the Illumina and Agilent arrays (Figs. 2A and C). The
H19 DMR maps 2–4.4 kb upstream of the H19 transcription start site
(TSS) (Imprinted Gene Catalogue Records: http://igc.otago.ac.nz).
This particular region is not represented on either array, due to the
presence of tandem repeats within the H19 DMR [13]. The H19
promoter is also known to be differentially methylated in human
WBCs [14]. There are two CpG sites on the Illuminamicroarray, located
between the promoter and the DMR, and as expected gain of
methylation was observed at these sites (Fig. 2B) in the LPID11_HP
sample compared to controls.
Interestingly, the high passage cell line from the healthy individual
LM4_HP showed reduced methylation (β value=0.18) at one of the
CpG sites upstream of the H19 transcription start site (genomic
location 1977136, build 36), whereas all other samples from WBCs of
healthy individuals had β values ranging from 0.4 to 0.46, indicating
that methylation at CpG sites within DMRs can be altered in high
passage LCLs (Fig. 2B).Methylation patterns at imprinted DMRs in LCLs
We analyzed known DMRs involved in the regulation of imprinted
gene expression for changes in methylation patterns in LCLs from
normal individuals, using both the Illumina and Agilent data. We
checked 19 genomic regions that harbor known/potential DMRs
[13,15–25]. The coordinates of the DMRs were taken from the
Imprinted Gene Catalogue Records (http://igc.otago.ac.nz), when
available, or were deduced from published data (Supplementary
Table 1). The Illumina Inﬁnium methylation array is reported to be
accurate for β-value differences ≥0.2 (20%). Therefore this value was
chosen as cut off for methylation differences. We set cut off levels of
log2 ratio=0.6 (1.5 fold change in methylation) in at least two
contiguous probes for the Agilent data. This methylation difference
between WBC and LCL of the same individual was required in order
for a methylation change at a DMR to be accepted. For HP_LCL
samples, for which we did not have an original WBC sample, the same
cut off level was used, but the comparison was between each HP_LCL
and all WBC samples run on this platform. Our assumption was that
the methylation levels in the WBC samples of healthy individuals,
from which HP_LCLs originated, are similar to those in normal WBC
samples used in this study (WM1, WF1, WM2, WF2, WF4).
The majority of the DMRs tested retained their methylation
patterns in LCLs. Methylation changes meeting the cut offs described
abovewere found in 5 genes. Thesewere DIRAS3, H19,MEG3,MKRN3,
NDN and NNAT (Tables 3, Supplementary Table 2). The regions with
altered methylation detected by microarrays are shown in Figs. 2B, 3,
Supplementary Fig. 1 and Supplementary Table 2. There were more
methylation changes occurring in HP_LCLs than in LP_LCLs and
Fig. 2.Methylation array data for two DMRs at chromosome 11p15.5. (A) Illumina data for the maternal KvDMR CpG site (genomic coordinate chr11:2676805). (B) Illumina data for
paternally methylated sites upstream of the H19 TSS (genomic coordinates chr11: 1976144 [black] and chr11: 1977136 [grey]. The X axis shows sample ID and the Y axis shows
methylation values from 0 (not methylated to 1 (fully methylated). (C) Agilent CpG island microarray data integrated into UCSC Genome Browser for two samples: healthy control
(LM1_LP) and patient with paternal UPD of chromosome 11 (LPID11_HP). The location of microarray probes within a CpG island is shown by black and grey bars. The probes are
approximately 50 bp long. The height of each bar represents quantile normalized log2 ratios of methylated DNA/total DNA from hybridization signals for a single microarray probe.
This corresponds to the level of methylation, i.e. higher methylation levels will correspond to higher bars. The LPID11_HP sample compared to control shows the expected reduction
of methylation at KvDMR.
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individuals were limited to two CpG sites and included both gains
and losses. Gain of methylation was detected at 4 Illumina CpG sites
and two Agilent probes for the NNAT promoter in the LPID11_HP
sample from a BWS patient. This gain of methylation was detected by
both arrays, because it occurred in several consecutive CpG sites
(Supplementary Fig. 1).
To see if the DNA methylation changes detected in LCLs by the
Illumina platform are limited to single CpG sites from the array, or
expanded into surrounding CpGs, we designed pyrosequencing assays
targeting the CpG site from the Illumina and several adjacent CpGs, forthree genes: DIRAS3, H19, and NNAT. These assays were used to test
the samples that were run on the array and additionally one pair of
WBC and low passage LCL: WF5 and LF5_LP. DNA methylation values
detected by Illumina and pyrosequencing are shown in Fig. 3. For H19
a CpG site with loss of methylation in LM4_HP from the Illumina array
and 4 distal CpGs were tested by pyrosequencing. We found that DNA
methylation changes in LM4_HP were limited to only one CpG site
from Ilumina array, whereas adjacent CpGs retained normal methyl-
ation patterns (Fig. 2B).
For the DIRAS3 a CpG site (CpG7, Fig. 3D) with gain of methylation
in LF3_HP and LPID11_HP and 6 distal CpG sites were tested by
Table 3
Methylation changes at known DMRs found in LCLs.
Gene Position of DMR in
the human genome
Source of
coordinates
IC Parent of origin
methylation
Agilent met.
change
Illumina met. change Pyro met. change
DIRAS3 exon1 chr1:68288822–
68289107
Luo et al.2001 Unkn Putative
maternal (E)
No Gain in 1 CpG site in LM3_HP, LF3_HP,
LPID11_HP
Gain in 2 CpGs in LF3_HP,
LPID11_HP, 1 CpG in LF5_LP,
loss in 1 CpG site in LF3_HP
H19 DMR chr11:1977641–
1980041, 2–4.4 kb
upstream H19 TSS
http://igc.otago.
ac.nz
Yes Paternal N/A Loss in 1 CpG site in LM4_HP
(outside of IC)
Loss in 1 CpG site in LM4_HP
MEG3 chr14:100359582–
100361600
Rosa et al. 2005 No Paternal No Loss in 2 CpG sites in LF3_HP, 1 CpG
site in LM2_LP, LM4_HP, LPID11_HP
N/A
MKRN3 Promoter/exon1 Horsthemke and
Wagstaff 2008
No Maternal N/A Loss in 3 CpG sites in LF3_HP, 1 CpG
site in LF1_FR, LM3_HP, LM4_HP
N/A
NDN Promoter/exon1 Horsthemke and
Wagstaff 2008
No Maternal No Loss in 2 CpG sites in LM3_HP, 1 CpG
site in LM2_LP, LM2_FR, LF1_LP, LF1_FR,
and all HP_LCLs
N/A
NNAT chr20:35580503–
35584711
Evans et al. 2001 Unkn Putative
maternal (M,E)
Gain in 2 probes
in LPID11
Loss in 1 CpG in LM3_HP, gain in 2 CpGs
in LF2_LP, 1 CpG in LF2_FR and LF3_HP,
and 4 CpGs LPID11_HP
Gain in 3 CpGs in LF2_LP,
LF2_FR, LF3_HP, LPID11_HP
LF5_LP, loss in 3 CpGs
in LM3_HP
Positions of DMRS were either taken from http://igc.otago.ac.nz, or deduced from the cited papers. If parent of origin methylation is unknown in human, it was designated as
putative, either based on mouse homology(M) and/or pattern of expression of downstream gene (E). N/A means information is not available due to the lack of the probes on the
array. Unkn means unknown, regarding whether the DMR is an imprinting centre (IC).
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and one adjacent CpG in both LF3_HP and LPID11_HP. Additionally,
gain of methylation of CpG7 was found in LM5_LP, and loss of
methylation was found in CpG1 in LF3_HP (Fig. 3D).
For NNAT the CpG site with loss of methylation in LM3_HP and
gain of methylation in LF2_LP and LF2_FR and two distal CpG sites
were validated by pyrosequencing. We observed losses and gains of
methylation concordant with array data in all three sites and all three
cell lines (Fig. 3F). Additionally we observed gain of methylation in all
three sites in LF3_HP and LPID11_HP, which was also seen in the
Illumina array, although slightly smaller than the set cut off of 0.2
methylation difference. We also found that there was gain of
methylation for all three sites in LF5_LP compared to its WBC sample.
In summary we found that only a single CpG out of 5 CpGs was
susceptible to methylation change for H19, whereas 2 out of 7 and 3
out of 3 CpGs were susceptible to DNAmethylation change for DIRAS3
and NNAT respectively. Therefore we conclude the effect of cell
culturing can be variable in terms of the length of the affected region.
Differential methylation analyses of Agilent CpG island microarrays
We identiﬁed themethylation changes between LM1_LP andWM1
samples ﬁrst on Agilent microarrays, then checked the methylation
patterns in the identiﬁed regions on Illumina arrays or by pyrose-
quencing. We tested additional WBC/LP_LCL pairs in order to verify
whether these DNAmethylation changes occur in all or just a subset of
the LCLs, i.e. are they site-speciﬁc or random?
To set the parameters for the detection of methylation changes on
the Agilent arrays we used the known methylation differences in
samples LPID11_HP and LM1_LP. The LPID11 sample has paternal
isodisomy of chromosome 11 in 85–90% of the cells and thus partial
loss of methylation (17%) at maternal KvDMR (Fig. 2C). We adjusted
the Partek GS analysis parameters in order to detect the difference in
KvDMR methylation in the LPID11 sample (17%) compared to the
methylation level in the LM1 sample (52%). These parameters were
set to detect a 3-fold (52%/17%) and higher methylation change in 5
or more contiguous probes.
Using these parameters we searched formethylation differences in
the LM1_LP sample compared to the WBC sample of the same
individual, WM1. We detected 41 altered genomic regions, of which
three were hypomethylated and 38 were hypermethylated in LM1_LP
compared to WM1 (Table 4).
To check whether methylation changes found in LM1_LP are
random or site-speciﬁc we further validated three regions using
bisulphite pyrosequencing in 5 pairs of WBCs and LP_LCLs. As well weanalyzed 6 regions using the Illumina platform in 4 pairs of WBCs and
LP_LCLs.
UNC93B1, HTR1A and hsa-mir-339 (MIR339) were the genes
selected for pyrosequencing. Primers for pyrosequencing were
designed within the region of the altered DNA methylation, targeting
3 to 5 CpG sites per assay. For each sample, methylation values were
averaged for all CpG sites within the assay. Microarray data, together
with pyrosequencing results, are shown in Fig. 4A and Supplementary
Fig. 2A. As Agilent data do not provide the percentage of methylation,
we could not make a direct comparison between the pyrosequencing
and Agilent data. However, we observed the same direction of change
in methylation on the validation by pyrosequencing. For the UNC93B1
and hsa-mir-339 regions, we observed loss of methylation in all 5 LCLs
tested, and for HTR1A we observed gain of methylation in 4 out of 5
LCLs tested.
Probes within 6 genomic regions (FAM84A, HOXA9, DLX5, WT1,
HSPA2, IRX5) detected as different in LP1_LP versus WM1 by Agilent
arrays were also present on the Illumina array. Therefore Agilent and
Ilumina data could be cross-validated. The coordinates of the Illumina
CpG sites are shown in Table 4. All of these regions were found to be
hypermethylated in LM1_LP by Agilent. We observed the same
direction of methylation change on Illumina in the WM1/LM1_LP
sample pair (Fig. 4B, Supplementary Fig. 2B). Five of the six gains of
methylations found in LM1 did not occur in all 4 LCLs tested by
Illumina (Fig. 4B, Supplementary Fig. 2, right panel). Thus, these gains
of methylation occur in only a subset of LCLs, i.e. these changes in
methylation are not site-speciﬁc. Only gain of methylation within the
WT1 gene was present in all 4 LCLs tested.
Thus themajority of gains of methylation (6 of 7) detected in LCLs
represent changes that occur at random genomic locations. To
determine the potential shared functionality of the genes acquiring
methylation in LM1_LP, we used GO stat ontology analysis to identify
the ontology categories which might be signiﬁcantly overrepresent-
ed (p-value b0.01). The overrepresented genes fall into 67 different
GO categories, showing that genes with many variable functions
demonstrate gain ofmethylation in LCLs.We also did not observe any
pattern in terms of the location of the DNA methylation changes
relative to the transcription start of the gene (upstream, down-
stream, exonic, intronic) (Table 4).
In contrast to gain of methylation, loss of methylation in LM1_LP
was detected for only three genes. The methylation status of two of
them was conﬁrmed by pyrosequencing in 5 WBCs/LCLs pairs,
indicating that loss of DNA methylation in LCLs could be more site-
speciﬁc than gain of methylation.
Fig. 3. DNAmethylation proﬁles of single CpG site selected from the Illumina array analysis and corresponding pyrosequencing assay. For Illumina, β-values were transformed into %
of methylation. The Illumina CpG sites within pyrosequencing assays are shown by arrows. The patterns of arrows are consistent between left panel (Illumina) and right panel
(Pyrosequencing) to indicate the cell lines where a methylation change was found in Illumina array. The CpG sites within the pyrosequencing assay are ordered according to their
position in the genome. Note that differences in % absolute values between Illumina and pyrosequencing could be due to ampliﬁcation biases (towards ampliﬁcation of un-
methylated allele in pyrosequencing). (A) Illumina % DNA methylation at CpG site chr11:1977136 located upstream of H19 promoter TSS. (B) % DNA methylation determined by
pyrosequencing at 5 consecutive CpG sites upstream of H19 TSS. (C) Illumina % DNA methylation at CpG site chr1:68288376 located in exon1 of DIRAS3. (D) % DNA methylation
determined by pyrosequencing at 7 consecutive CpG sites in DIRAS3 exon1. (E) Illumina % DNA methylation at CpG site chr20:35582535 located in the NNAT gene. (F) % DNA
methylation determined by pyrosequencing at 3 consecutive CpG sites in the NNAT gene.
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Table 4
Genomic regions with differences in DNA methylation between WM1 and LM1_LP samples.
CHR Start End Length, bp State # probes Overlapping genes (±10 kb) Position relative to the gene Illumina
7 1029308 1029564 257 −4.7 5 C7orf50, hsa-mir-339 intron2 C7orf50, 5′ of hsa-mir-339 No
11 67526925 67527274 350 −4.7 5 UNC93B1, ALDH3B1 exon3 UNC93B1, 5′ of ALDH3B1 No
19 16297914 16299151 1238 −4.7 14 KLF2 exon1/intron1 KLF2 No
2 14690488 14691009 522 4.7 5 FAM84A intron1 of FAM84A 14690908
2 119323820 119324191 372 4.7 6 EN1 5′ of EN1 No
2 176654328 176654697 370 4.7 5 EVX2 intron2 of EVX2 No
4 134291974 134292355 382 4.7 5 PCDH10 exon1 of PCDH10 No
4 174687959 174689038 1080 4.7 9 HAND2 5′ of HAND2 No
5 2803353 2803720 368 4.7 5 IRX2 intron1 of IRX2 No
5 3649976 3650264 289 4.7 5 IRX1 intron1 of IRX1 No
5 38592975 38593348 374 4.7 5 LIFR intron1/5′ of isoforms of LIFR No
5 63292612 63293068 457 4.7 6 HTR1A exon1 of HTR1A No
5 72712528 72712837 310 4.7 5 None N/A No
5 72776250 72776559 310 4.7 5 FOXD1 3′ of FOXD1 No
5 170668435 170668820 386 4.7 6 TLX3, RANBP17 5′ of TLX3, RANBP17 No
6 94184107 94184732 626 4.7 7 EPHA7 intron1 of EPHA7 No
6 101953405 101953889 485 4.7 7 GRIK2 5′ and exon1 of GRIK2 No
7 1236249 1237112 864 4.7 9 UNCX 5′ of UNCX No
7 1245154 1245511 358 4.7 5 UNCX 3′ of UNCX No
7 8449611 8449945 335 4.7 5 NXPH1 intron 2 NXPH1 No
7 27171824 27172255 432 4.7 5 HOXA7, HOXA9, HOXA10 5′ of HOXA7, HOXA9, 3′ of HOXA10 27172004
7 96489326 96489820 495 4.7 5 DLX5 exon/intron2 of DLX5 96489522
8 23619167 23619655 489 4.7 6 None NA No
10 131654094 131654647 554 4.7 7 EBF3 5′ of EBF3 No
11 20137724 20138119 396 4.7 6 DBX1 exon1/intron1 of DBX1 No
11 20138485 20138963 479 4.7 7 DBX1 5′ of DBX1 No
11 32411958 32412537 580 4.7 7 WT1 intron 1 of WT1 32412311
12 21985705 21986138 434 4.7 5 ABCC9 5′ of ABCC9 No
13 52320388 52320934 547 4.7 6 PCDH8 5′ and exon1 of PCH8 No
13 57105096 57105607 512 4.7 7 PCDH17 exon1 PCDH17 No
13 57105937 57106322 386 4.7 6 PCDH17 exon1 of PCDH17 No
13 111771263 111771606 344 4.7 5 SOX1 exon1 of SOX1 No
14 37747128 37747533 406 4.7 6 SSTR1 intron1 of SSTR1 No
14 56344670 56345360 691 4.7 8 OTX2 intron1 or 2 of isoforms of OTX2 No
14 64078497 64079033 537 4.7 6 ZBTB1, HSPA2, C14orf50 exon2 of HSPA2, 5′ of ZBTB1 and C14orf50 64079018
14 78815066 78815433 368 4.7 6 NRXN3 5′ or intron 5 of NRXN1 isoforms No
15 72212252 72212678 427 4.7 7 ISLR2 exon1or 4 of isoforms of ISLR2 No
16 49745429 49746274 846 4.7 10 SALL1 5′ of SALL1 No
16 53522988 53523474 487 4.7 7 IRX5 5′ or intron1 of isoforms of IRX5 53522993
17 76930513 76931022 510 4.7 7 None N/A No
18 18002502 18002878 377 4.7 5 GATA6 5′of GATA6 No
Start and end length indicate start and end of the region showing changes in methylation. State: if positive shows gain of methylation in LM_LP and if negative loss of methylation in
LM1_LP. Overlapping genes column shows the genes present within 10 kb of the detected region. The regions selected for pyrosequencing validation are shown in grey. The Illumina
column shows the genomic coordinate of a CpG site. CHR is chromosome.
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In this paper, we compared genome-wide methylation proﬁles of
WBC samples, low-passage LCLs pre and post freezing from four
individuals and four unrelated high-passage LCLs. Our results show
that DNA methylation proﬁles of LCLs and WBCs of the same
individual are not identical (correlation coefﬁcients=0.933–0.947).
It is in agreement with data of Brennan et al. [26], who studied
differences in methylation of 318 genes using Sequenom's MassAR-
RAY in 6 pairs of WBCs and LCLs, and found that 8% of these genes
showed different methylation in LCLs compared to WBCs. This
difference is not surprising, because LCLs originate from B-lympho-
cytes; themethylation proﬁle for that cell type could be different from
the pool of all white blood cells. Additionally EBV-transformation and
cell culturing can potentially induce methylation changes. For
example, Wilson and Jones [27] found that global methylation levels
tend to decrease in ﬁbroblasts over time in culture, whereas
immortalized cell lines maintain more stable levels of methylation.
We further looked at the correlation of methylation patterns in
LCLs to determine whether alterations occur at speciﬁc or random
genomic locations. The correlation coefﬁcients were very high
between WBC samples (0.985–0.99) indicating very small inter-
individual variation, but dropped signiﬁcantly for LCLs pair-wise
comparisons, which were especially profound for the cell lines with ahistory of multiple passages (Table 2). These data indicate that
methylation changes occurring in the LCL do not affect all cell lines
equally, e.g. a given genomic location can demonstrate altered
methylation in one cell line but not in another. Surprisingly, the
effect on methylation of one cycle of freezing was no stronger than
that of just short term culturing.
We compared the regions with consistent changes in methylation
across several probes in one WBC/LCL pair using the Agilent array,
followed by validation of several regions using the Illumina array and
pyrosequencing. This analysis revealed that the majority of gains of
methylation (6 out of 7) detected in LCLs represent changes that do
not occur in all WBCs/LCLs pairs and that they affect genes with
variable functions. However, loss of methylation was detected in
only three genes, and was shown for two of those genes to affect all
WBCs/LCLs pairs. We suggest that loss of methylation detected in
LCLs compared to WBCs might reﬂect differences in methylation
between B-lymphocytes and other sub-types of WBCs, whereas gain
of methylation represents random effects of cell culturing. In support
of this, all three hypomethylated genes detected in LCLs by the
Agilent platform have known functions in subtypes of white blood
cells: UNC93B1 in B-cells [28], hsa-mir-339 in the human leukemic
HL-60 cell line, which originates from peripheral white blood cells
[29], and KLF2 in T-cells [30]. In contrast hypermethylated genes
have variable gene functions.
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genes, we observed changes in LP_LCLs, FR_LCLs and HP_LCLs in three
imprinted genes MKRN3, NDN and NNAT. DIRAS3 and MEG3 wereaffected in LP_LCLs and HP_LCLs, but not in FR_LCLs, indicating again
that one cycle of freezing has less effect on DNA methylation than
culturing. H19 was affected in only one HP_LCL line. Interestingly,
none of the affected imprinted regions are located within known
imprinting centres. MEG3, NDN and MKRN3 harbor secondary DMRs
dependent on imprinting centers within bigger imprinting clusters
[23,25]. For single imprinted genes DIRAS3 and NNAT differential
methylation levels were observed in somatic tissues [17,20]; however,
it is unknown if these regions are primary ICs for these genes. The CpG
site upstream of the H19 transcription start site showed loss of
methylation in the HP_LCL sample. It is located outside of the region
deﬁned as the H19 DMR or IC1 of the 11p15.5 imprinted cluster [13].
These data suggest that ICs might be more resistant to methylation
change in cell lines than other genomic regions.
The observed changes in LCLs indicate that these cells may not be
an optimal screening tool for identiﬁcation of putative imprinted
DMRs by DNA methylation analysis, as DNA methylation levels could
shift from the expected 50% due to cell culturing. The expression of
imprinted genes could also potentially shift from monoallelic to
biallelic due to methylation changes in LCLs or vice versa. As
approximately 10% of human genes exhibit random patterns of
monoallelic expression within single clones of LCLs [31], monoallelic
expression in LCL could lead to a false conclusion that a gene is
monoallelically expressed due to imprinting, when in fact it would be
biallelic in a sub-population of these cells.
Overall, DNAmethylation analysis inWBCs and three types of LCLs,
in imprinted DMRs and genome-wide, showed that two initially very
similar methylation patterns can become more and more different as
the cell line undergoes multiple cell divisions.
A variety of mechanisms could induce random methylation
changes in LCLs. One possibility is a model proposed by Antequera
et al. [32] that any gene with an associated CpG island has a signiﬁcant
probability of becoming inactivated by DNA methylation, and if this
occurs for a gene essential for survival, the cell will die. Alternatively
when the gene is not essential for survival in cell culture, the cell
survives carrying the altered methylation pattern, and may even have
a selective advantage [32]. This model explains gain of methylation
rather than loss and is consistent with our data that demonstrate
more frequent random gain of methylation in LCLs.
Another possible reason for non-speciﬁc changes in DNA methyl-
ation could be clonality of the LCLs. Plagnol et al. examined X
inactivation skewing as a measure of clonality in 1174 female LCLs,
and found nearmonoclonality in 20% of the cell lines [33]. Also Simon-
Sanchez et al. [1] observed that the ratio of cells with non-germ line
heterosomic deletions was reduced in LCLs compared to the original
WBC samples, probably due to the putative selective advantage of
cells carrying the full diploid genome. The same mechanism could be
true for methylation. If the initial population of cells was mosaic for a
methylation change in a speciﬁc gene, a clonal increase for this
speciﬁc change could shift the percentage of methylation. If this
mechanism is important, the number of non-speciﬁc changes should
accumulate with increases in cell divisions, which is what we
observed.
In summary, we have shown that lymphoblastoid cell lines are
prone to DNA methylation changes at random genomic locationsFig. 4. (A) Agilent CpG island microarray data integrated into the UCSC Genome
Browser for two samples: LM1_LP and WM1 within hsa-mir-339 promoter. The height
of each bar represents quantile normalized log2 ratios of methylated/total DNA from
hybridization signals for a single microarray probe. This corresponds to the level of
methylation, i.e. higher methylation levels will correspond to higher bars. The line is
drawn at log2 ratio=0.8, which approximately equals 50% methylation. (B) Validation
of array data within hsa-mir-339 promoter by pyrosequencing in 5 pairs of WBCs and
LP_LCLs. (C) Agilent data for region of hypermethylation in the LM1_LP sample
compared to theWM1 samplewithin DLX5 gene. (D) Illumina data for 1 CpG site within
detected DLX5 gene for 4 pairs of WBCs and LP_LCLs.
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be taken when identifying disease-associated DNA methylation
variants in LCLs. Conﬁrmation of such alterations should be carried
out in primary cell types.
Materials and methods
Research subjects
The study was approved by the Research Ethics Board of the
Hospital for Sick Children (Toronto). Informed consents were
obtained from all individuals.
Lymphoblastoid cell line establishment
Lymphoblastoid cell lines were established in the Biobanking
facility, The Centre for Applied Genomics, The Hospital for Sick
Children, Toronto, Canada according to standard procedures [34] or
purchased from NGIMS Human Genetics Cell Repository, Coriell
Institute of Medical Research (Camden, NJ) (http://ccr.coriell.org/).
DNA samples for microarray and pyrosequencing
Four matched sets of white blood cells (WBC) and low passage
lymphoblastoid cell lines pre (LP_LCL) and post freezing (FR_LCL)
from the same individuals were used in this study for LCL/WBC DNA
methylation comparison by microarray. One additional pair of WBC/
LP_LCL was used for pyrosequencing. Four unmatched high passage
LCLs (HP_LCL) and one WBC sample were used for microarrays. A cell
line with paternal isodisomy for chromosome 11 was used to validate
microarray data and to optimize the Agilent microarray analysis
parameters. For LP_LCLs cells were cultured after EBV transformation
to 4×107 cells, 4 vials of ∼8×106 cells were frozen and ∼5×106 cells
were cultured to 2×107 cells (which is equivalent to growing up to
16×107 cells if no freezing is done). For FR_LCLs, 8×106 cells were
thawed and grown up to 2×107 cells. For HP_LCLs, it was not possible
to track the previous history of growth/freezing.
DNA was extracted from 2×107 LCLs and 5 ml of whole blood
using phenol-chloroform and ethanol precipitation. Sample informa-
tion, including cell type, age, sex, source and application used are
listed in Table 1.
MeDIP and Agilent CpG island microarray
Analysis of DNA methylation proﬁles was performed using
methylated DNA immunoprecipitation (MeDIP) followed by Human
244K Agilent CpG island microarray (Agilent, Santa Clara, CA) which
contains 237,220 probes, covering 27,800 CpG islands (97.5 % of UCSC
annotated CpG islands). The probes are 45–60 bp in length and are
spaced at 100 bp from the middle of each probe to the next.
MeDIP was performed as initially described by Weber et al. [11]
with slight modiﬁcations. Brieﬂy, 10 μg of 5mC antibody (Eurogentec,
San Diego CA) was incubated with 50 μl of Dynabeads ® M-28 Sheep
anti-mouse IgG (Invitrogen, Burlington, ON) for 5 h in IP buffer
(10 mM Na phosphate pH7.0, 140 mM NaCl, 0.05% Triton X-100) at
4 °C. Genomic DNA was sonicated to the sizes 200–1000 bp using the
Sonicator® Ultrasonic Liquid Processor, Model XL2000 (Misonix,
Farmingdale, NY). 4 μg of DNA was added to the Antibody-beads
complex and incubated overnight at 4 °C. The DNA-Antibody-
Dynabeads complex was washed three times with IP buffer, and
incubated in TE pH 8.0, 1% SDS solution with 5 μl of Protein K (10 mg/
ml) for 2 h at 55 °C. DNA was further puriﬁed using the Qiaquick PCR
puriﬁcation kit (Qiagen, Mississauga, ON).
Immunoprecipitated DNA (21 μl) and 250 ng of sonicated
genomic DNA of the corresponding sample of MeDIP DNA was
labeled using BioPrime® Array CGH Genomic Labeling (Invitrogen)
Cyanine 3-dCTP and Cyanine 5-dCTP (Perkin Elmer, Waltham, MA)
respectively.Puriﬁcation of labeled products, array hybridization and scanning
were performed at the Microarray facility, The Centre for Applied
Genomics, The Hospital for Sick Children, Toronto, Canada according
to the Agilent Microarray Analysis of Methylated DNA Immunopre-
cipitation Manual (Version 1.0, May 2008).
Data from scanned images (tiff) were extracted using Feature
extraction software version 9.0 (Agilent), Human Agilent CpG version
20070207 grid ﬁle and CGH V4-91 protocol.
Analysis of Agilent CpG island microarray
Agilent microarray data were analyzed using the Partek Genomic
Suite (PGS) software according to the algorithm developed by
Sadikovic et al. [35]. The feature extraction ﬁles were imported into
Partek GS as red (Cy5, MeDIP fraction) and green (Cy3, total genomic
DNA fraction) processed signals. The datawere normalized to baseline,
by dividing red signal (MeDIP fraction) by green signal (total genomic
DNA fraction), log2 transformed and quantile normalized for all the
arrays. Thus, data were represented as log2 (methylated DNA/total
DNA) after inter-array normalization for each probe of the array.
Higher log2 ratios correspond to highermethylation levels. An ANOVA
tool was used to calculate the fold change in methylation for each
probe between samples. The Hidden Markov Model (HMM) was
applied to the fold change of each probe to identify regions of
contiguous probes with similar fold change in methylation. The
parameters of HMM were adjusted in order to identify known
methylation difference in the LPID11_HP sample at the maternally
differentially methylated region KvDMR (11p15.5) compared to the
LM1_LP sample. The level of methylation was 17% in LPID11_HP and
52% in LM1_LP sample, according Illumina array data. The following
cut-off were used after optimization (min. probes 5, detection states
−4.7, 4.7, ignore state 0, max. probability 0.99, genomic decay 10,000,
sigma 1) to compare WM1 and LM1_LP samples. These parameters
were set to detect approximately 3-fold (51/17) and higher
methylation changes in 5 or more contiguous probes.
The detected regions of differences in methylation were annotated
using refFlat.txt.gz ﬁle (overlap 10, 000 upstream and downstream)
downloaded from the UCSC genome browser, and containing themost
updated annotation of RefSeq genes. The microarray data were
visualized in the UCSC genome browser by creating wig ﬁles for each
chromosome containing normalized log2 (methylated DNA/total
DNA) ratios for each sample.
Illumina's inﬁnium HumanMethylation27 BeadChip
The HumanMethylation27 BeadChip (Illumina, San Diego, CA)
contains 27,578 individual CpG sites covering 14,000 genes. Methyl-
ation status of the interrogated CpG site is measured as the ratio of
signal from a methylated probe (C not converted to T) relative to the
sum of both methylated (C not converted to T) and unmethylated
probes (C bisulﬁte-converted to T). 1 μg of genomic DNA was bisulﬁte
converted with Imprint® DNA Modiﬁcation Kit according the
manufacturer's protocol (Sigma, Oakville, ON). Whole genome
ampliﬁcation, labeling, hybridization and scanning were performed
at the Genetic Analysis facility, The Centre for Applied Genomics, The
Hospital for Sick Children, Toronto, Canada.
Analysis of Illumina methylation data
The methylation ratios (β value=C/(T+C)) were extracted using
the Methylation Module in the Illumina Bead Studio after average
normalization. This β value ranges continuously from 0 (unmethy-
lated) to 1 (fully methylated). The correlations among samples and
hierarchical clustering were performed in Bead Studio (Illumina). The
number of detected probes (p-valueb0.05) was very high for all
arrays and varied between 99.3% and 99.9%.
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All genome coordinates used in this paper are according to Build
36 of the human genome annotation.
Bisulﬁte pyrosequencing
DNA methylation analysis by pyrosequencing were performed as
described by Tost and Gut [36]. Pyrosequencing assays containing two
PCR primers and one sequencing primer were designed to target 3–7
CpG sites using PSQ Design Software (Biotage, Uppsala, Sweden). One
of the PCR primers had a universal tagwhich annealed to the universal
biotinylated primer. Genomic DNA (1 μg) was bisulﬁte convertedwith
Imprint® DNA Modiﬁcation Kit (Sigma) according to the manufac-
turer's protocol and eluted in 20 μl of water. Bisulﬁte converted DNA
(1 μl) was ampliﬁed using Hot-Start Taq-polymerase (Qiagen).
Amplicons were analyzed on the Luc 96 pyrosequencer as speciﬁed
by the manufacturer (Biotage), and % methylation was quantiﬁed as a
ratio of C (methylated C, not converted to U) to T(not-methylated C
converted to U) using Pyro Q-CpG Software (Biotage). The primer
sequences are shown in Supplementary Table 3.
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